CompletedNCT02633527

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Medication studyAges 6–12United States

The study in practice

Understand this study

This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: February 1, 2016

Recruitment status: Completed
Enrollment listed in the registry: 222
Sponsor: Supernus Pharmaceuticals, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 6 Years to 12 Years
Official registry ID: NCT02633527
Official title: Show the full official title
Evaluation of the Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD - A Double-Blind, Placebo-Controlled, Dose-Ranging Study

Completed

Maitland

FAQ

Who is behind this study?

The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812 and 400mg SPN-812.

Who was this study for?

This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.